Table 2.
BRV discontinuation by comorbidity and by etiology (FAS)
| Patients, n (%) | CLD comorbidity | Psychiatric comorbidity | Post-stroke epilepsy status | BTRE status | TBIE status | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| With CLD N = 403 |
Without CLD N = 1232 |
With psychiatric comorbidity N = 605 |
Without psychiatric comorbidity N = 1011 |
With post-stroke epilepsy N = 51 |
Without post-stroke epilepsy N = 1397 |
With BTRE N = 68 |
Without BTRE N = 1380 |
With TBIE N = 49 |
Without TBIE N = 1399 |
|
| BRV discontinued | 149 (37.1)a | 400 (32.6)b | 185 (30.7)c | 357 (35.4)d | 17 (33.3) | 471 (33.8)e | 27 (39.7) | 461 (33.5)f | 13 (27.1)g | 475 (34.1)h |
| Reason for BRV discontinuationi | ||||||||||
| Lack of effectiveness | 81 (55.1)j | 161 (40.7)k | 79 (43.4)l | 159 (44.9)m | 3 (17.6)n | 224 (48.2)o | 8 (29.6)p | 219 (48.1)q | 7 (53.8)r | 220 (46.9)s |
| Tolerability | 40 (27.2)j | 150 (37.9)k | 66 (36.3)l | 122 (34.5)m | 6 (35.3)n | 153 (32.9)o | 11 (40.7)p | 148 (32.5)q | 2 (15.4)r | 157 (33.5)s |
| Lack of effectiveness and tolerability | 26 (17.7)j | 47 (11.9)k | 31 (17.0)l | 41 (11.6)m | 6 (35.3)n | 53 (11.4)o | 4 (14.8)p | 55 (12.1)q | 0 | 59 (12.6)s |
| Other | 7 (4.8)j | 55 (13.9)k | 13 (7.1)l | 49 (13.8)m | 2 (11.8)n | 59 (12.7)o | 5 (18.5)p | 56 (12.3)q | 3 (23.1)r | 58 (12.4)s |
| Cost | 4 (2.7)j | 8 (2.0)k | 3 (1.6)l | 9 (2.5)m | 0 | 12 (2.6)o | 1 (3.7)p | 11 (2.4)q | 1 (7.7)r | 11 (2.3)s |
| BRV availability | 1 (0.7)j | 1 (0.3)k | 0 | 2 (0.6)m | 0 | 2 (0.4)o | 0 | 2 (0.4)q | 0 | 2 (0.4)s |
| BRV discontinued due to tolerability | ||||||||||
| In the first 3 months | 28 (19.2)t | 69 (17.6)u | 41 (22.9)v | 56 (15.9)w | 6 (37.5)x | 88 (19.0)y | 8 (29.6)p | 86 (19.0)z | 2 (15.4)r | 92 (19.7)aa |
| Between 3 and 6 months | 17 (11.6)t | 69 (17.6)u | 34 (19.0)v | 49 (13.9)w | 3 (18.8)x | 60 (13.0)y | 4 (14.8)p | 59 (13.1)z | 0 | 63 (13.5)aa |
| Between 6 and 12 months | 14 (9.6)t | 38 (9.7)u | 14 (7.8)v | 38 (10.8)w | 3 (18.8)x | 35 (7.6)y | 2 (7.4)p | 36 (8.0)z | 0 | 38 (8.2)aa |
BRV brivaracetam, BTRE brain tumor–related epilepsy, CLD cognitive/learning disability, FAS full analysis set, TBIE traumatic brain injury–related epilepsy
an = 402; bn = 1228; cn = 603; dn = 1008; en = 1392; fn = 1375; gn = 48; hn = 1395; iReasons for BRV discontinuation were not mutually exclusive; jn = 147; kn = 396; ln = 182; mn = 354; nn = 17; on = 465; pn = 27; qn = 455; rn = 13; sn = 469; tn = 146; un = 392; vn = 179; wn = 352; xn = 16; yn = 463; zn = 452; aan = 466